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Abstract 
 
 
Neuropathic pain is a complex chronic condition which affects the somatosensory 
system, poorly managed with the conventional treatments despite the immense 
advances in pain treatment strategies. Damage of peripheral nervous system, due to 
injury or disease, leads to abnormal responses to painful and not-painful stimuli; 
conventional analgesics can only alleviate pain in acute situation, and finding an 
effective treatment which can relief chronic neuropathic pain remains still 
challenging. 
Mammalian STOML3, a MEC-2 homologue, is a member of a large family of stomatin 
proteins characterized by a common stomatin domain, expressed by DRG sensory 
neurons involved in regulation of mechanosensation, which is required for normal 
mechanoreceptor function. Previous data revealed that in STOML3 null mice 30-40% 
of Aδ and Aβ fibers lacked all mechanosensitivity; in addition, tactile behaviors are 
impaired and symptoms of neuropathic pain in CCI mice are also largely attenuated 
(Wetzel et al, 2007). 
Here I investigated the mechanisms by which STOML3 acts as an important 
contributor in the neuropathic pain symptoms and I demonstrate that small molecule 
modulation that both reversibly silence mechanoreceptors in vivo and attenuate 
touch perception in mice can reverse established neuropathic pain symptoms, making 
STOML3 a promising novel peripheral target for the treatment of sensory disorders. 
 
 
 
Keywords: primary sensory neurons; stomatin-domain proteins; touch; sensory 
transduction; neuropathic pain; chronic-constriction injury; behavioural assessment; 
CLARITY method; immunochemistry; molecular biology. 
 
7 
 
 
1. Introduction  
 
 
1.1 Neuropathic Pain 
 
Diabetic neuropathy, viral infections, major surgeries, spinal cord injury, stroke: these 
are just few examples of a wide range of conditions underlying the etiology of 
neuropathic pain, a complex pathological syndrome which can lead to serious 
disability and has an important impact on the population (it has been estimated that 
8% of Europeans is affected).  
As early as childhood, we all have experienced  the physiophathological modifications 
that occur following tissue damage, establishing deep but reversible pain 
hypersensitivity in inflamed and surrounding tissue in order to assist the wound 
repair; on the other hand, tissue damage either in peripheral (i.e. peripheral nerves, 
dorsal root ganglia, dorsal roots) or in central nervous system (i.e. spinal cord, 
thalamus) might lead to abnormal responses of the body and chronic disorders, 
which characterize various forms of neuropathies.  
     From a clinical point of view the occurrence of neuropathic pain is often 
characterized by stimulus-independent persistent pain, a spontaneous syndrome that 
may depend on both activity of sympathetic nervous system and spontaneous firing 
of C-fibre nociceptors, or stimulus-dependent pain, further sub-classified according to 
the stimulus that triggers it. Within the latter is comprised one of the key features of 
neuropathic pain, so-called touch-evoked pain or allodynia (Woolf & Mannion, 1999).    
The term hyperalgesia is nowadays defined as an increased pain response to a 
suprathreshold noxious stimulus resulting from an abnormal input processing, 
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whereas allodynia leads to pain perception on exposure to normally innocuous tactile 
stimuli; it thus represents  a form of pain due to a innocuous stimulus, resulting from 
low-threshold sensory fiber excitation.   
So far, despite the advances in understandings the mechanisms underlying the 
various disorders following peripheral injuries, no effective treatment has been found 
yet; some patients may not respond to common therapeutic strategies such as not-
steroidal anti inflammatory drugs, or they may develop resistance to opioids. 
Furthermore, local anesthetics have short-lived effects while antidepressants and 
anticonvulsants have limited efficacy and too many side effects. Patients may develop 
even no pain or limited reduction of it after administration of tolerated doses of drug; 
therefore, there is a need for more effective analgesics and novel strategies for 
analgesics drug development. 
 
 
 
1.2 Mechanisms of peripheral neuropathic pain  
 
1.2.1 Stimulus-independent pain 
One of the most dramatic symptoms that characterize peripheral neuropathies is a 
spontaneous and severe pain experience. Stimulus-independent or ongoing pain is 
actually very hard to assess in preclinical studies due to the difficulty in its evaluation 
in animal models; however, physiological and pharmacological changes underlying 
stimulus independent pain have been well investigated. 
Peripheral nerve damage leads to an initial burst of high-frequency discharge 
followed by ectopic activity generated in the DRGs and neuroma at the site of the 
lesion (Chen and Devor, 1998; Xie et al., 1995). Spontaneous firing is recorded in both 
injured and neighbors not-injured fibers, from the early post-lesion period (12h-
3days) which lasts over two months paralleling abnormal pain behaviors (Kim, Yoon, 
& Chung, 1997). 
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This hyperexcitability has been related to Na+ channel plasticity (Baker & Wood, 
2001; Devor, Jänig, & Michaelis, 1994); after nerve injury, Na+ channels accumulates 
at the neuroma site and along the axon length, drives to foci of excitability and action 
potential discharge in injured sensory neurons. Unluckily, conventional treatments 
with Na+ channels blockers are not specific and give a wide range of side-effects. 
 Sympathetic nervous system plays also an important role in spontaneous pain 
maintainement, due to an over-expression of α-adrenoreceptors and a consequent 
hypersensitivity to circulating catecholamines. Sympathetic fibers sprouting forming 
pericellular baskets around the soma of DRGs sensory neurons has also been 
reported  (McLachlan et al., 1993). Moreover, GABAergic tone reduction in the dorsal 
horn and both GABA and opioid receptors down-regulation enable disinhibition of 
excitatory impulses with subsequent lowering of peripheral nociceptive thresholds 
(Gwak et al., 2008), making opiates and GABA-mimic drugs a useful therapeutical 
approach. 
 
 
1.2.2 Touch-evoked pain 
It has been widely reported that, under normal conditions, the specific stimulation of 
thin weakly-myelinated Aδ-fibers and unmyelinated C-fibers triggers nociceptive 
pain,   while light touch sensation is selectively carried by low-threshold Aβ-fibers, 
whose activation normally does not evoke pain. 
By contrast, one of the major features of neuropathic pain syndrome is that the 
activation of low threshold Aβ-fibers, which normally triggers innocuous light touch 
sensation, is now able to cause intense pain (Costigan, Scholz, & Woolf, 2009; Lewin & 
Moshourab, 2004; von Hehn, Baron, & Woolf, 2012). 
Central sensitization through sustained activation of nociceptors plays a key role in 
mechanical hyperalgesia; glutamate release following nociceptors activation 
depolarizes the dorsal horn neurons; inflammatory mediators and neuropeptides 
such Substance P are also released, extending the depolarization and increasing the 
intracellular Ca2+ concentration, matching the reduction of the GABAergic tone in the 
spinal cord. Central sensitization causes an enlargement of the peripheral area in 
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which the stimuli can activate the neurons, increasing of the responses to a supra-
threshold input and in making subthreshold inputs reach the threshold and initiate a 
action potential. 
Aβ-fiber-mediated pain may also result from A-fibre sprouting in lamina II of the 
spinal cord dorsal horn. Under normal conditions lamina II only receives nociceptive 
information; sprouting of A-fibers in lamina II leads to misreading of innocuous 
stimuli as noxious by the Central Nervous System (CNS) (Woolf et al., 1994). 
Moreover, a phenotype switching of A-fibers has also been reported after peripheral 
injury. Calcitonin gene-related peptide (CGRP) and Substance P (SP) play an 
important role in pain processing and hyperalgesia, and they are normally released 
by C- and Aδ-fibers. Following peripheral lesion, they have been shown to be down-
regulated in medium and small- sized cells but released from large-myelinated Aβ-
fibers (Miki et al., 1998); thus, even innocuous stimuli which activate Aβ-fibers might 
cause release of CGRP and Substance P in the dorsal horn leading to central 
hyperexcitability. 
 
 
1.2.3 Spinal glia response at peripheral injury 
Microglia, astrocytes and oligodendrocytes represent altogether about 70% of the 
entire cell population in brain and spinal cord. At spinal level, microglia plays a key 
role in the pathogenesis of neuropathic pain. Spinal microglia establishes the first 
noticeable response in spinal cord after several type of peripheral insults. Upon 
activation, it has been shown to act as a “linker” between the initial injury and the 
long term neuronal plasticity leading to pain amplification, and the functional and 
phenotypic pattern of activation strongly depends on the type of peripheral stimulus.  
It has been shown that the number of microglial cells and astrocytes increases in 
spinal dorsal horn ipsilaterally to a peripheral nerve injury (Aldskogius & Kozlova, 
1998). After 4h following L5 transection, the microglia activation markers toll-like 
receptor 4 and cluster determinant 14 mRNA are up-regulated and subsequently 
decline after 28 days (Tanga, Raghavendra, & DeLeo, 2004). The astrocyte marker 
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glial fibrillary acidic protein is upregulated as well, starting on postoperative day 4 
through day 28 (Tanga et al., 2004).  
Upon activation, microglia produces and releases substances including cytokines, 
prostaglandins, nitric oxide and excitatory amino acids such as glutamate, that act as 
hyperalgesia mediators. Thus, it has been proposed that microglia is the first 
immunoeffector cell sensor that, if inhibited before the onset of astrocyte activation, 
may prevent mechanical hyperalgesia in various models of neuropathy (Tanga et al., 
2004). Indeed, selective blockade of glial cells activation prevents and reverses 
abnormal pain sensitivity: selective inhibition of glial metabolism by fluorocitrate 
intrathecal administration results in a marked and reversible attenuation of thermal 
and mechanical hyperalgesia; blockade of CX3C receptors reverses hyperalgesia 
when applied 5-7 days after sciatic nerve CCI (Milligan et al., 2004). When microglia 
grown in culture and activated by ATP are injected intrathecally in rats, mechanical 
hyperalgesia similar to that observed after spinal nerve ligation is induced, while 
inactive microglia have no effect (Tsuda et al., 2003).  
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1.3 Models of induced- neuropathy in mice 
 
Development of animal models that reproduce symptoms of human neuropathic pain 
has been critical in order to elucidate the neurobiological mechanisms underlying the 
change in the function, chemistry, and structure of neurons in neuropathic pain. 
Whereas spontaneous ongoing pain is hard to assess and quantify in preclinical 
studies due to the technical difficulty in measuring its signs in rodents behavior, 
abnormal responses to thermal-, chemical- or touch-evoked pain can be well 
assessed. For this reason, effects of hypothetical analgesic compounds are largely 
evaluated on their effects in allodynia and hyperalgesia, with minor effort on 
spontaneous pain.  
     Chronic constriction Injury of the sciatic nerve (CCI) (Bennett & Xie, 1988) is one of 
the most frequently animal models used for the study of neuropathic pain molecular 
mechanism and for the evaluation of pharmacological treatments. This model is 
based on a unilateral loose ligation of the sciatic nerve enough to occlude but not to 
arrest the epineural blood flow. However, this causes a near complete loss of large 
myelinated fibers distal to the ligature in rats (Basbaum, 1991) as a result of direct 
damage on the afferents.  
CCI model produces many of the properties of neuropathic pain in humans; in 
addiction, it has been demonstrated to be responsive to a wide numbers of 
compounds which are clinically used as analgesic treatment. CCI leads to a 
reproducible symptomatic response characterized by decreased threshold in paw 
withdrawal following thermal, mechanical and chemical stimulation; specific pain 
behaviors at the injured paw such as shaking or licking; abnormal posture of the 
injured paw (i. e. toes held together), with an onset within 24 hours until 8-12 weeks. 
Thus CCI, combined to pain hypersensitivity behavioral tests, provides a reliable 
system to investigate the effectiveness of potential therapeutic agents. 
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     Peripheral neuropathic pain is produced by multiple etiological factors that initiate 
a number of diverse mechanisms operating at different sites and at different times; it 
is unlikely that a single animal model will include the full range of the neuropathic 
pain mechanisms.  
Another model which has been investigated in this work is the spared nerve injury 
(SNI) model (Decosterd and Woolf, 2000), which has been recently developed as an 
additional animal model of persistent neuropathic pain. It involves a lesion of two of 
the three terminal branches of the sciatic nerve (tibial and common peroneal nerves) 
leaving the remaining sural nerve intact. The SNI model differs from the Chung spinal 
segmental nerve, the Bennett chronic constriction injury and the Seltzer partial sciatic 
nerve injury models in that the co-mingling of distal intact axons with degenerating 
axons is restricted, and it permits behavioral testing of the non-injured skin 
territories adjacent to the denervated areas.  The spared nerve injury results in early 
(< 24h), prolonged (>6 months) and robust behavioral modifications.  
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1.4 Somatosensory mechanotransduction 
 
Everything we feel around us and our capability to detect the wide variety of stimuli 
we are every day in contact with is gated by our somatosensory system. It enables us 
to detect and interpret our environment, serving also an essential protective function 
by mediating fundamental physiological function as the sight, smell, hearing, and 
sense of touch and pain.  
     Mechanotransduction is the mechanism by which cells convert a specific 
mechanical stimulus in an electrical signal, letting us even discriminate between 
different textures of surfaces. As a general mechanism, the detection of the wide 
range of mechanical and painful stimuli is performed by primary sensory neurons, 
whose cell bodies are located outside the spinal cord in a swelling called Dorsal Root 
Ganglia (DRG). Sensory neurons emit a single axon which split in two branches that 
act as single axons, called distal and proximal processes. The distal process projects 
to the skin  where they form specialized mechanoreceptors that are tuned to detect 
mechanical forces such as stretch and vibration, turning them in action potential that 
bypasses the neuron cell body and continue to propagate along the proximal process, 
until it will be delivered to a second neuron located in the spinal cord; then the signal 
will follow an ascendant way passing through thalamus and finally it will reach the 
cerebral cortex for its final interpretation. 
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1.4.1 Anatomy of mammalian mechanotransduction 
Mechanoreceptors act like “gates” which selectively respond to mechanical forces by 
causing membrane depolarization in the receptive field.  Such depolarization let the 
sensory afferents to transduce sensory stimuli into action potential firing through 
activation of mechanotransducer channels located on sensory nerves endings.  
These selective encoding devices are disseminated throughout the body on skin, 
viscera and tendons. Mammalian cutaneous receptors are morphologically and 
physiologically so far the best known: hair follicles are responsible for light touch 
perception, Merkel-complexes detect skin-stretch, Pacinian corpuscle detects vibratory 
stimuli and Meissner corpuscles respond to dynamic skin deformation. By contrast, 
free nerve endings are not connected to auxiliary structures and only respond to 
noxious forces.  
All this wide and various set of information are detected and transmitted by different 
arrays of somatosensory afferents, which are usually classified in sub-groups based 
on axonal diameter and myelin thickness that confers them well defined 
electrophysiological properties: 
 Large-diameter and thick myelinated Aβ-fibers are very rapidly conducting fibers 
and detect innocuous mechanical stimuli (Lewin et al. 2004). They innervate 
defined mechanoreceptors both in hairy and glabrous skin. 
 Medium-diameter and lightly myelinated Aδ-fibers are slowly conducting and can 
either connect to skin hairs with a light-touch detection function, or lose the 
myelin sheath and innervate the skin as free-ending nociceptors. 
 Small-diameter and unmyelinated C-fibers nociceptors terminate as free endings 
in the skin and respond to all types of noxious stimuli in a slow-adapting manner.  
The size of the afferents reflects the cell body size of sensory neurons, and 
mechanosensory signaling relies on specific cellular morphologies. Peripheral 
sensory fibers, before joining and entering together in the spinal cord via the dorsal 
root, reach a swelling, called Dorsal Root Ganglion, which hosts cell bodies of primary 
sensory neurons.  
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The latter are classified in subpopulations based on their anatomy, neurochemistry 
and physiology (Lawson et al., 1992).  Large-size neurons represent about 40% of the 
entire population, send out myelinated axons that fell in the Aβ-fiber range and 
receive input from peripheral mechanoreceptors (Sommer, Kazimierczak, & Droz, 
1985); medium-size neurons give off thin myelinated axons which conduct in the Aδ-
fibers range, while small-size neurons emit unmyelinated fibers which act as 
nociceptors (McCarthy & Lawson, 1990). 
 
 
1.4.2 Physiology of mechanotransduction 
How mechanical sensory cells convert mechanical forces in electrical signs in 
vertebrates and the nature of the transduction molecules involved together with the 
developmental events that lead to specification of the appropriate sensory neuron 
sub-types are still matter of study. 
Excitatory ion channels are essential in touch reception, but despite genetic screens 
in C. elegans already permitted to identify some of them in invertebrates (Deg/ENaC, 
TRP channel families), further investigations have to be done in mammalians. 
Consistent genetic and molecular evidences lead to propose a tether model of 
mechanotransduction. In this model the ion channel, which represents the “core” of 
the complex, has been supposed to be “tethered”, or anchored by intra- and 
extracellular domains both to cytosketeton and extracellular structures, to which 
forces are applied; in this way, deflections of the anchor points lead to a conformation 
change of the ion channel enhancing its open-status probability.  
Although the exact composition of many components of the mechanotransduction 
machinery is still matter of study, several ion channels have been propose to be 
involved in touch sensation. Studies in transgenic models recently found novel touchy 
ion channels called Piezo family (Coste et al., 2010) as well as touch modulatory 
proteins which influence touch sensitivity through a modulatory role such as 
STOML3 (Wetzel et al., 2007). 
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1.4.3 From C. Elegans to mammals:  discovering molecules involved in touch 
sensation 
The tiny nematode Caenorhabditis elegans (C. Elegans) has been a powerful tool in 
studying various aspects of cell development and function. 
In the early 80s, Chalfie and Sulston approached touch development by mutational 
analysis in C. elegans, obtaining more than 500 mutations in about 15 genes which 
result in loss of touch sensation. Most of these genes, called mec (from 
mechanosensory abnormal), encode for proteins that are part of the 
mechanotransduction machinery (Fig. 1, a).  
From these studies came out the first molecular model for eukaryotic 
mechanosensation: 
 Subunits MEC-4 and MEC-10 physically interact in assembling the transducing 
channel, which is the core of the complex; 
 The channel extracellular domains are thought to be linked to the extracellular 
matrix by associating with the MEC-5 collagene-like molecule and/or MEC-9; 
 The channel extracellular domains are hypothesized to be linked with the unique 
15-protofilaments microtubule (constituted of MEC-12 α-tubuline and MEC-7 β-
tubulin) by associating with the stomatin-related peripheral membrane linker 
protein MEC-2, which is exclusively expressed by mechanoreceptor neurons and 
show homology with stomatin, an integral membrane protein found in many cell 
types and involved in the homeostasis of the cell. 
Thus, in this model the channel is stretched between two attachment points. The 
tethering of the channel subunits both to the extracellular matrix and the 
cytoskeleton confer channel gating tension; mechanical deflections cause the channel 
opening by changing the conformation of mechanotransduction machinery (Fig. 1). 
Since quite a lot of intriguingly touchy genes came from C. Elegans genetic screening, 
subsequent search for orthologs in other species, and of course in mammals, revealed 
a number of proteins which might be part of mammalian mechanosensory machinery.  
In C. Elegans, Degenerin (DEG) genes encode for proteins related to the vertebrate 
epithelial Na+ channels (ENaCs); since mutations in such genes are related to touch 
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impairments in C. elegans, a role in mechanotransduction for the vertebrate homologs 
has been proposed. 
Acid-sensing ion channels ASICs proteins are activated by extracellular protons and 
mediate pain induced by acidosis; they were proposed to form the ion channel, even 
though mouse mutants revealed only mild alteration in mechanosensation (Price et 
al., 2001; Roza et al., 2004). 
Piezo proteins have been recently revealed as the mammalian mechanotransduction 
ion channels (Coste et al., 2010) and Piezo 2 as the major transducer of mechanical 
forces in mice (Ranade et al., 2014). By virtue of its ability to potently modulate Piezo 
channels (Poole, Herget, Lapatsina, Ngo, & Lewin, 2014; Wetzel et al., 2007),  
STOML3, the MEC-2 mammalian orthologous, has been recently demonstrated to be 
an essential protein in transducting touch sensation.  
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Figure 1. (a) Scheme of C. elegans mechanotransducting multiprotein complex formed by 
MEC proteins. (b) A scheme of mechanotransduction machinery in mammals based on the 
homology of several MEC proteins to mammalian proteins; so far, only STOML3 has been 
implicated in mechanotransduction.  
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1.5 Stomatin family of proteins 
 
MEC-2 protein, the best functionally characterized in C. Elegans, is 65% identical to 
stomatin in its central domain, while the N- and C- terminus are not conserved 
(reviewed in Lapatsina et al., 2012) 
Stomatin family of proteins, which include the members Stomatin, STOML1, STOML2, 
STOML3 and Podocin, share 40-84% of similarity in the sequence of the characteristic 
stomatin central domain of ~120 residues. They have a similar membrane topology 
and, with the exception of STOML2 which doesn´t have a hydrophobic domain (Green 
& Young, 2008), the primary domain organization. All members have different 
expression patterns and different subcellular distributions. 
Stomatin-domain proteins can regulate both ion channels and transporter proteins. 
The structure of the stomatin central domain, which has been found in all  kingdoms 
of life, has been recently solved as an integral membrane protein anchored to the 
plasma membrane via both a hairpin-like hydrophobic domain and a palmitoylation 
whose building block is a banana-shape dimer which oligomerizes at the membrane 
(Brand et al., 2012) (Fig. 2).  
Stomatin dimerization is crucial for their ability to modulate both ASIC proteins and 
mechanosensitive ion channels like Piezo1 and Piezo2 (Brand et al., 2012; Poole et al., 
2014). By using a newly developed assay based on elastometric pili, it has been 
demonstrated that the sensitivity of Piezo channels is exquisitely tuned by STOML3 
(Poole et al., 2014). Ongoing work seeks to examinate the precise in vivo function of 
other poorly understood stomatin domain-containing proteins, such as STOML1, for 
which, by means of advanced cellular imaging techniques in combination with 
transgenic mouse models, an unexpected role in metabolic disorders has been 
demonstrated (unpublished data).  
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1.5.1 Stomatin-like protein 3 (STOML3)  
Stomatin family proteins, in particular STOML3, play an essential role in the 
transduction of mechanical stimuli in vertebrates and invertebrates (reviewed in 
Lapatsina et al., 2012). STOML3, the mammalian homologue of MEC-2, is an integral 
membrane protein and an essential accessory subunit for nematode touch receptors 
(Goodman et al., 2002; O’Hagan, Chalfie, & Goodman, 2005). 
Starting from genetic observations of around 15 genes (mec) whose function is 
necessary for touch sensation in C. Elegans, mammalian hortologues of mec genes 
were identified, cloned and characterized. Creation of mice with mutant alleles for 
these genes was crucial to study the in vivo role of the stomatin protein family 
members in touch sensation and physiology, demonstrating that STOML3 is indeed 
the MEC-2 hortologous and a crucial subunit in touch sensation (Wetzel et al., 2007) 
Loss of mechanically activated currents in cultured DRG neurons is expected to be 
associated with a loss of mechanosensitivity of sensory fibers in the skin (Wetzel et 
al., 2007); Stoml3-/- mice combined with ad hoc assays as ex-vivo skin nerve 
preparation revealed that ~35% of mechanoreceptors were completely insensitive to 
mechanical stimuli (Fig. 3).  STOML3 mutants have also severe deficits in their ability 
to detect such textural surfaces with much reduced tactile acuity (Wetzel et al., 2007).  
Subjecting wild type and stoml3-/- mice to a unilateral sciatic nerve chronic 
constriction injury (CCI), wild type mice developed a full-blown allodynia; in contrast, 
stoml3-/- mice did not show any hyperalgesia until the third day post-lesion and they 
developed much milder symptoms. STOML3 null mice are thus largely protected from 
touch-evoked pain following nerve injury, even though no changes in 
mechanosensitivity were found in C- fibers (Wetzel et al., 2007). In addition, no 
impairment was found on the CCI-induced thermal hyperalgesia was found in   
stoml3-/- mice.  
Like stomatin, STOML3 is also capable of inhibiting the amplitude of acid-gated 
currents mediated by ASIC proteins;  in the absence of STOML3 in mice, proton gated 
currents are larger in sensory neurons (Wetzel et al., 2007).  
There is a substantial loss of mechanosensitivity in stoml3-/- mice in which ~35% of 
the myelinated fibers lack a mechanosensitive receptive field and this phenotype was 
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found to be identical in asic3-/-:stoml3-/- mutant mice. Aδ-nociceptors showed much-
reduced mechanosensitivity in asic3-/-:stoml3-/- mutant mice compared to asic3-/- 
controls.  Loss of stomatin or STOML3 in asic3-/- or asic2-/- mutant mice markedly 
exacerbates deficits in the mechanosensitivity of nociceptors without affecting 
mechanoreceptor function (Moshourab, Wetzel, Martinez-Salgado, & Lewin, 2013).  
STOML3 is a powerful positive modulator of Piezo channel 
mechanosensitivity; structure-function experiments localize the Piezo modulatory 
activity of STOML3 to the stomatin domain, and higher-order scaffolds are a 
prerequisite for function (Poole et al., 2014). 
These data revealed that STOML-3 is not only necessary for the function of 
mammalian mechanotransduction complexes but also plays a physiological role in 
regulating ASIC and Piezo channels in sensory neurons.  
Moreover, STOML3 seems to be a promising potential molecular target that directly 
participates in the transduction of noxious and innocuous mechanical stimuli in 
sensory neurons; thus, targeting essential mechanotransduction molecules such as 
STOML3 might provide a novel peripheral means to control sensory disorders.  
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(from Lapatsina et. Al, European Journal of Cell Biology, 2001).  
Figure 2. (a) STOML3 is an integral membrane protein with a single, short and hydrophobic 
membrane insertion domain followed by the core stomatin domain. A single conserved 
proline residue in the hydrophobic region is required for the formation of the hairpin 
structure. Both N-and C-termini are intracellular. (b) A homology model of trimeric STOML3, 
based on the known crystal structure of the Pyrococcus horikoshii (ph) stomatin trimer was 
created using SWISS-MODEL (Brand et al., 2012). 
 
 
 
(from Wetzel et al., Nature, 2007) 
Figure 3. electrophysiological recordings show that about 35% of mechanosensitive fibers do 
not respond to mechanical stimuli in Stoml3 (SLP3) null mice compared to wild type, while 
no changes in C-fibers was found. 
 
 
  
STOML3 
-/-
 
WT 
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1.6 Objectives of the study 
 
Neuropathic pain is a debilitating condition for which so far no treatment has been 
found to be really effective; some patients may not respond to common therapeutic 
strategies, local anesthetics have short-live effects while antidepressants and 
anticonvulsants have limited efficacy and too many side effects. 
    Touch-evoked pain has been assumed to be primarily driven by low threshold 
mechanoreceptors in humans. STOML3, the mammalian homologue of MEC-2, has 
been demonstrated to be an essential subunit in modulating mechanotransduction; 
the intriguingly and unique effect of STOML3 ablation in mechanosensation and the 
surprising findings that STOML3 null mice are largely protected from touch-evoked 
pain unraveled a novel interesting role of STOML3 in pathophysiology, making this 
protein a potential pharmacological target for the treatment of neuropathic pain. 
    The purpose of this work was primarily focused in understanding the STOML3 role 
in neuropathic conditions and whether modulation of mechanotransduction by 
directly acting on STOML3 function might be a novel strategy in the effective 
treatment of sensory disorders.   
In particular, by means of murine models of neuropathic-induced pain combined with 
behavioral tests for pain assessment, I demonstrate that STOML3 is indeed an 
important protein whose function is required for conferring hypersensitivity to 
mechanical stimuli under neuropathic pain conditions in vivo. In addition, I provide 
novel evidence that STOML3 disruption results in the loss of touch-evoked pain 
symptoms, making the protein a powerful tool for treating sensory disorders 
resulting from direct damage of afferent fibers. 
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2. Materials and Methods 
 
2.1  Neuropathic pain mouse models and behavioral pain 
assessment 
 
2.1.1 Surgery 
Chronic constriction injury of the sciatic nerve (CCI). Mice were deeply 
anesthetized by an induction chamber with 3,5% isoflurane in O2. After shaving the 
right hind leg, the shaved area was sterilized with application of 70% isopropyl 
alcohol. An incision in the skin parallel, but 3-4 mm below the femor, was made, 
leaving the skin free from the muscles surrounding the incision by cutting through 
the connective tissue. A retractor was used to widen the gap between the muscles 
gluteus superficialis and biceps femoris, allowing a clear visualization of the sciatic 
nerve. Approximately 10 mm of sciatic nerve was gently exposed from the 
surrounding connective tissue. 
Four loosely constrictive silk ligatures (5/0; Catgut GmbH Markneukirchen) with a 
double knot, 1 mm apart, were placed around the sciatic nerve at the level of the right 
mid-thigh. Ligatures were the tied until they elicited a brief twitch in the respective 
hind limb to prevent epidural blood flow. Staples (9 mm) were used to fasten the skin.  
Spare nerve injury (SNI). Mice were anesthetized using isoflurane delivered in 
100% O2 (Univentor 410 Anaesthesia Unit; Univentor, Malta). After shaving the skin 
at the mid-tight, a skin and muscle incision was made and the sciatic trifurcation, 
nerve pieces (2-4 mm) of the sural as well as the common peroneal nerves were 
removed leaving the tibial nerve intact. Wounds were closed with wound clips before 
anesthesia was termined.  
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2.1.2 Assessment of touch-evoked pain: Von-Frey up-down method 
Mice were allowed to habituate to the testing apparatus (acrylic chambers 5.5 x 10 
cm in size) suspended above a wired mesh grid, one hour before the behavioral 
testing. Once the mice were resting and not moving, calibrated von-Frey hair 
monofilaments (Aesthesio® set of 20 monofilaments, Ugo Basile) were applied on the 
plantar surface of the hind paw in order to deliver target forces from 0.008 to 4 grams 
increasing in a logarithmic scale.  A single stimulus indicated by a slight bending of 
the stimulus lasted for two seconds unless the mouse withdrew his paw. In order to 
measure mechanosensitivity the up-and-down method described by Chaplan et al., 
(1994) was adapted as follows: testing began with a filament delivering a target force 
of 0.4 grams, and every filament is applied three times. A positive response was noted 
if the mouse withdrew the paw to all the three filament application, so that the 
successively smaller filament was presented next. A negative response was noted if 
the mouse did not respond to at least one out of three applications, and in this case 
the subsequent larger filament was presented next. Paw withdrawal thresholds were 
calculated as median of 23 to 30 determined turning points of the particular force 
stimuli applied to the mouse. 
 
2.1.3 Assessment of thermal hyperalgesia:  Hargreaves´s method 
Mice were allowed to habituate into a glass chamber (Ugo Basile) one hour before the 
behavioral testing. Test was performed on the plantar surface of the hind paw by a  
focused, radiant heat light source (IITC Life Science Inc.).  
The light beam was focused to the top of a built-in heating base digitally controlled 
for consistent temperatures (in this study: 32°C) and created a 4x6mm intense spot 
on the hind paw of the mouse. The time needed to paw withdrawal in response to a 
constantly increasing heat stimulus (maximal active intensity: 25% of the light 
source) with a cut-off of 20 seconds was determined. Heat stimuli were repeated 5 
times for each paw with a stimulus interval of 1 minute.  
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2.1.4  Statistical analysis  
All data set were tested for normality. All normally-distributed data sets were 
compared using a two-tailed Student´s t test. In all cases * indicates p < 0.05; ** 
indicates p < 0.01 and *** indicates p < 0.001. 
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2.2 Molecular biology 
 
 
Tab 1. Kits and enzymes 
name supplier 
TURBO DNA-free™ Ambion® 
SuperScript™ III Reverse 
Transcriptase 
Invitrogen GmbH (Gibco), Karlsruhe, Germany 
Universal Mastermix Roche 
 
 
Tab 2. Chemicals 
name supplier 
Chloroform  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Ethanol Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Isopropanol Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Glycogen Invitrogen GmbH (Gibco), Karlsruhe, Germany 
Trizol Invitrogen GmbH (Gibco), Karlsruhe, Germany 
OligodT Invitrogen GmbH (Gibco), Karlsruhe, Germany 
Random nonamers Invitrogen GmbH (Gibco), Karlsruhe, Germany 
dNTPs 
Invitrogen GmbH (Gibco), Karlsruhe, Germany 
5X First-Strand Buffer 
Invitrogen GmbH (Gibco), Karlsruhe, Germany 
DTT 
Invitrogen GmbH (Gibco), Karlsruhe, Germany 
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10X buffer 
Invitrogen GmbH (Gibco), Karlsruhe, Germany 
MgCl2 
Invitrogen GmbH (Gibco), Karlsruhe, Germany 
Taq Polimerase 
Invitrogen GmbH (Gibco), Karlsruhe, Germany 
MasterMix 
Invitrogen GmbH (Gibco), Karlsruhe, Germany 
Agarose 
Invitrogen GmbH (Gibco), Karlsruhe, Germany 
 
 
 
2.2.1 Genotyping  
Stoml3-/- mice genotyping was carried out by polymerase chain reaction amplification 
with genomic DNA isolated from mice tail biopsies. The total reaction volume was 20 
µl including the DNA sample. The reaction buffer was made as follows:  
 
Standard PCR mic for Taq polymerase Cycling protocol 
2 µl 10X buffer 94°C   7 min 
1 µl MgCl2 60°C   35 sec 
0.4 µl dNTPs 72°C   2 min 
0.2 µl primer 3´ 94°C   30 sec 
0.2 µl primer 5´ 60°C  35 sec 
0.2 µl Taq polymerase 72°C  2 min, 30 cycles 
 
DNA samples were separated on 1% agarose gel in the EasyCast™ gel system (Owl 
Thermoscientific). Gel was prepared by microwaving the appropriated amount of 
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agarose powder in 1X SB buffer. 0.01% of Ethidium Bromide was added to the pre-
cooled agarose solution and the gel was poured into the gel slides and allowed to 
polymerize. DNA samples were mixed with 6X loading dye and ~500 ng DNA were 
added per gel pocket. The Smart DNA ladder (Eurogen) was used as a DNA-size 
marker. Electrophoresis was carried out at 70-120 V for 15-25 min and gels were 
afterward analyzed using the Safe Imager™ blue light (Invitrogen). 
 
2.2.2 Extraction of total RNA from tissue and cells 
Lumbar DRGs (L4-5-6) and olfactory bulb were dissected and immediately 
transferred in 800 µl of Trizol reagent containing 200 µg glycogen (final 
concentration 250µg/ml) followed by homogenization by power homogenization. 
Samples were placed 5 minutes at room temperature, and 160µl of chloroform were 
added afterwards. After vigorous vortexing for 30 seconds, samples were incubated 
for 3 minutes on the bench. To separate total RNA, samples were centrifuged for 10 
minutes at 12000g, 4°C, and the upper acqueous phase containing RNA was 
transferred into a fresh tube. For RNA precipitation 400 µl of ice-isopropanol were 
added, and samples were incubated at -20°C overnight. The day after, RNA was pellet 
by centrifugation at maximum speed 15 minutes at room temperature. After 
supernatant was decanted, RNA pellet was washed in 200 µl of 70% ethanol and 
spinned again at maximum speed. The washing phase was repeated or 3 times. 
Supernatant was decanted without disturbing the pellet; RNA was air-dried and the 
pellet was resolubilized in 30 µl RNAse-free deionized water. 
Tissue culture cells were extensively mixed with TRIZOL with no homogenization 
step before chloroform addition; the RNA then extracted as described before.  
 
2.2.3 DNA cleaning 
DNA was cleaned out from RNA as follows: 0.1 volume of 10X TURBO DNase buffer 
and 1 µl Turbo DNase were added to the RNA. After mixing gently, the samples were 
incubated at 37°C for 20-30 minutes.  
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0.1 volume of DNase Inactivation reagent was added and after mixing samples were 
incubate 5 min at room temperature, flicking the tube occasionally during incubation 
period to redisperse the Dnase Inactivation Reagent. 
Samples were centrifuged at 10000g for 1.5 min to pellet the DNase Inactivation 
Reagent, and the cleaned RNA was transferred to a fresh tube.  
The quantity and purity of RNA were assessed using a NanoDrop 2000 UV-Vis 
spectrophotometer (Thermo Scientific). 
 
2.2.4 cDNA synthesis  
1.5-2 µg of RNA were used for cDNA synthesis. In a fresh sterilized 0.2 ml tube the 
following reagents were added: 
 1µl of oligo(dT)20 or 50-250 ng of random primers; 
 Total RNA 
 1 µl 10 mM dNTP Mix (10 mM each sATP, dGTP, dCTP and dTTP at neutral pH) 
 Sterile, distilled water to 13 µl 
The reaction was placed at 65°C for 5 min and incubate on ice for at least 1 min 
immediately afterwards. After collecting the contents of the tube by brief 
centrifugation, the following reagents were added:  
 1 µl 5X First-Strand Buffer 
 1 µl 0.1 M DTT 
 1 µl of Superscript® III Retrotranscriptase 
After mixing gently by pipetting up and down, samples were incubated at 50°C for 60 
min and 70°C for 15 min. 
 
2.2.5 Quantitative Real-Time PCR 
The PCR was performed in an ABI PRISM® 7900HT (Applied Biosystem) detection 
system. Reaction for quantitative real-time PCR using TaqMan detection was 
modified as follows: 
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 3,5 µl of sterile, deionized water 
 0.2 µl forward primer  
 0.2 µl reverse primer 
 0.1 µl probe 
 5 µl MasterMix 
The reactions were performed in a 384-well plate capped with MicroAmp optical 
caps; after putting 9 µl of reaction mix in each well, 1 µl of cDNA was added. Absolute 
copy number was determined referring to a standard curve which was created by 
using serially diluted cDNA containing plasmid. Each sample was performed in 
triplicate; data are presented as mean of number of copies for 1500 ng of total RNA ± 
S.E.M. 
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2.3 Histology 
 
Tab 4.  Chemicals 
name supplier 
Rompun ® (2% Xylazin) Bayer Vital GmbH, Leverkusen, Germany 
Ketamine(10%) WDT eG, Garbsen, Germany 
PBS Invitrogen GmbH (Gibco), Karlsruhe, Germany 
Glutharaldehyde Sigma-Aldrich Chemie GmbH, Schnelldorf, Germany 
X-Gal(bromo-chloro-
indolylgalactopyranoside) 
Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Sucrose Sigma-Aldrich Chemie GmbH, Schnelldorf, Germany 
OCT Sakura Finetek, Zoeterwoude, Netherlands 
Aqua Polymount Polisciences, Inc. 
Paraformaldehyde Sigma-Aldrich Chemie GmbH, Schnelldorf, Germany 
NaOH Sigma-Aldrich Chemie GmbH, Schnelldorf, Germany 
Triton X-100 Sigma-Aldrich Chemie GmbH, Schnelldorf, Germany 
MgCl2 (50 mM) Invitrogen GmbH, Karlsruhe, Germany 
Sodium chloride Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Nonidet P-40 Sigma-Aldrich Chemie GmbH, Schnelldorf, Germany 
Na deoxycholate Sigma-Aldrich Chemie GmbH, Schnelldorf, Germany 
Dimethylformamide Sigma-Aldrich Chemie GmbH, Schnelldorf, Germany 
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Tab 5.  Buffers 
name composition 
0.5% Glutaraldehyde 0.5% Glutaraldehyde, 2 mM MgCl2, 1.25mM EGTA in PBS. pH-7.4 
4% PAF 
4% Paraformaldehyde, 2 mM MgCl2, 1.25mM EGTA in PBS. pH 7.2- 
7.4 
10X PBS 80g/l NaCl, 2g/l KH2PO4, 2g/l KCl, 21.6g/l Na2HPO4•7H2O 
X-Gal reaction buffer 
35 mM K4[Fe(CN)6]•3H2O, 35 mM K3[Fe(CN)6], 2mM MgCl2, 
0.02% Nonidet P-40, 0.01% Na deoxycholate, 10mg/ml X-gal in 
dimethylformamide in PBS 
 
 
2.3.1 Stoml3LacZ knock-in mice 
In our hands no commercial or custom-made antibodies against STOML3 were 
available and reliable for specific detection of endogenous STOML3 in DRG neurons. 
Bacterial β-galactosidase gene (Lac-Z) is a powerful tool to detect the cis-acting 
regulatory sequence activity. Therefore, we focused on the study of the STOML3 
promoter expression pattern by using an unpublished knock-in mice in which a β-
galactosidase cassette with a nuclear localization signal (NLS) was insert with the 
start codon of STOML3 gene (Fig. 4).  
Once introduced under the promoter of the gene of interest, the endogenous 
expression pattern and the time point in development when the gene is initially 
expressed can be detected with an enzymatic reaction. 
In Stoml3LacZ mice used for this study, the first exon of the gene was replaced with a β-
galactosidase coding sequence. The gene promoter and regulatory elements were 
preserved (Fig. 4). 
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2.3.2 Animal perfusion fixation  
Before the perfusion mice were anaesthetized with a mixture of Rompun + Ketavet. 
0.02 ml of Rompun (20 mg/ml Xylazine) and 0.1 ml of Ketavet (100 mg/ml Ketavet) 
were made in 0.4 ml of PBS, and the dose of 0.02 ml/g was injected intraperitoneally. 
Surgical-plane anaesthesia was assured by the absence of toe-pinch evoked reflexes. 
The thoracic cavity was opened by cutting the diaphragm from one lateral aspect to 
the other lateral aspect. Both lateral aspects of the rib cage were in a caudal to rostral 
direction up to the second rib and folded-back to expose the thoracic organs. The 
right atrial chamber was lacerated with scissors while the 25G perfusion needle 
attached to the saline syringe was carefully inserted into the left ventricular chamber 
of the hearth. Mice were perfused with ice-cold PBS until liver blanching, followed by 
4% PFA or 0,5% glutaraldehyde perfusion for 20 min.  
At the completion of the perfusion, lumbar DRGs, spinal cord, olfactory bulb and 
sciatic nerve, aimed for X-gal, were dissected out, post-fixed for 30 min in 4% 
glutharaldehyde and dehydrated in 30% sucrose at 4°C overnight. 
 
2.3.3 Detection of β-gal activity 
Dehydrated tissue samples were embedded in O.C.T. Tissue-Tek, frozen on dry-ice 
and placed at -80°C prior to use. For histochemical staining, glutaraldheyde fixed 
tissues were frozen and sectioned with a cryostat (Leica CM3050S), mounted on 
slides and allowed to dry at room temperature. The thickness of sections varied with 
the tissue type.   
Before the staining, slides were rinsed several times in 1XPBS on ice. Fresh X-Gal 
buffer was prepared for every experiment. Slides were placed into a histochemical 
chamber and incubated in X-gal buffer (1mg/ml) at 37°C; the time was dependent on 
the tissue time, generally 24 hours were requested for DRGs.  
Following the staining, slices were intensively washed several times in 1XPBS until 
the solution no longer turned yellow and cover-slipped with AquaPolymount, and 
then observed in Zeiss Axiovert 135 by Zen software.  
36 
 
 
2.3.4 Morphometry 
Morphometric analysis was performed on DRG neuronal cell profiles in digital images 
captured with a 20X objective magnification from 6 mice both naïve and neuropathic, 
respectively. The tissue slices were separated by at least 30 µm. Image J software was 
used to manually trace the outlines of cells in order to obtain cell areas, which when 
then converted in diameter using Excel. Histograms of frequency distribution were 
plotted using GraphPad Prism. 
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Figure 4. (a) Schematic representation of the linearised targeting vector, the wild type 
Stoml3 locus, and the mutated Stoml3LacZ allele before and after removal of the self excision 
neomicyne (cre, neo) cassette. A 12 kb genomic region of Stoml3 locus containing exon 1 
(black) NLS-LacZ (blue) DTA (yellow) the self excision neomycine cassette, loxP (red 
arrowhead) and Spel (S) restriction sites are depicted. Green lines indicate the predicted 
fragments sizes obtained after Spel digestion of Genomic DNA. A green bar shows the 5’ 
probe used for southern blot analysis shown in (b), blue lines indicate the predicted fragment 
sized obtaining by genotyping the tail genomic DNA as shown in (c).  
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2.4 CLARITY 
 
2.4.1 McGreen mice 
Mice were kindly provided by Helmut Kettenmann laboratory. In Cx3cr1GFP/GFP mice 
(McGreen mice) that were used for this study, both copies of the Cx3cr1 gene have been 
replaced by the enhanced Green Fluorescent Protein (eGFP) reporter gene. 
Homozygous mice for the Cx3cr1 gene are fertile, normal in size and do not display 
physical or behavioral abnormalities. 
 
 
Tab. 6 Chemicals 
name supplier 
FocusClear Cell Explorer Labs CO 
Va-044 initiator Wako Pure Chemical industries, Ltd 
Bisacrylamide BIO-RAD 
Acrylamide BIO-RAD 
Boric Acid Biozym 
SDS Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
NaOH Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
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Tab. 7  Hydrogel monomer solution 
Ingredient Final concentration 
Acrylamide 40% 4% 
Bisacrylamide 2% 0.05% 
VA-044 initiator 0.25% 
10X PBS 1X 
PFA 16% 4% 
dH2O to 400 ml 
 
 
Tab  8. Clearing solution 
Ingredient Final concentration 
Boric Acid 200mM 
Sodium Dodecyl Sulfate 4% 
NaOH to pH 8.5 - 
dH2O To 10L 
 
 
2.4.2 Hydrogel and Clearing solution preparation 
Ingredients showed in tab1 were mixed under the hood with special attention to 
temperature and safety precautions, keeping all components in ice to avoid 
polymerization. After 40 ml were distributed into 50 ml conical tubes on ice, tubes 
were sealed tightly and stored at -20°C until they were ready for use. 
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Clearing Solution was made under a hood with special attention to safety precautions. 
Ingredients in tab.2 were combined at room temperature while stirring, and NaOH 
was added until the pH has reached 8.5; the solution was stored at room temperature.  
 
 
2.4.3 Transcardial perfusion with hydrogel solution 
Frozen hydrogel monomer solution was thawed and mixed gently prior to perfusing, 
making sure there were not precipitates or bubbles in the solution.  
Adult mice were deeply anaesthetized with Rompun Xylazine plus Ketamine in PBS 
and perfused first with 20 ml of ice-cold 1x PBS and then with 20 ml of ice-cold 
hydrogel solution, maintaining a rate of perfusion of about 2 minutes for the 20 ml of 
each solution. 
Spinal cord was then dissected out and immediately placed in 20 ml of cold hydrogel 
solution in a 50 ml conical tube, covered in aluminum foil and incubated at 4°C for 24 
hours to allow for further diffusion of the hydrogel solution into the tissue. 
 
2.4.4 Hydrogel tissue embedding 
50 ml conical tube containing the tissue was placed in a desiccation chamber under 
the fume hood. Cap was opened sufficiently to allow gas exchange; the chamber was 
degassed for 10 minutes through a vacuum pump, and then the chamber was filled 
with argon gas for other 10 minutes.  
The chamber was then opened sufficiently to reach the tubes in order to tightly close 
the sample tube, carefully minimizing exposure to air. 
Tubes were submerged in 37° water bath for 3 hours until solution had polymerized.  
After 3 h, in a fume hood, the embedded tissue was extracted from the gel, and extra 
gel pieces were removed with gloved fingers.  
The samples were washed with 50 ml of clearing solution for 24 hours at room 
temperature to dialyze out extra PFA or monomer, and then they were washed 2 
more times for 24 hours each, to further reduce residual PFA, initiator or monomer.  
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2.4.5 Electrophoretic tissue clearing 
Tissues were placed in the electrophoretic chamber, putting one tissue in each 
chamber. Clearing solution was circulated through the chamber, with 25V applied 
across the tissue at 37 degrees for several days until the tissue became transparent. 
Alternatively, passive clearing was also made; tissue was in 37°C room while shaking 
for at least 4 weeks, until the tissue turned transparent.  
After several days, samples were washed with PBS-T twice for 24 hours each. 
 
2.4.6 Preparing the sample for imaging 
Samples were incubated in  FocusClear for 2 days protected from light. Samples were 
placed in a ad-hoc space built attaching a press-to-seal Silicone isolator in WillCo-
Dish°, surrounded with enough FocusClear to surround the tissue, ensuring not to 
introduce any bubble. Once the chamber was entirely filled with FocusClear, the 
chamber was sealed with a glass coverslip. Confocal images were taken with Zeiss 
Axio Observer z1 microscope using Zen imaging software (Zeiss). 
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Figure 5. (a) Tissue is cross-linked with formaldehyde (red) in presence of hydrogel 
monomers (blue) covalently linking tissue elements to monomers that are then polymerized 
into a hydrogel mesh. Electric field applied across the sample in ionic detergent actively 
transport micelles into, and lipids out of the tissue, leaving fine structures and crosslinked 
molecules in place. (b) A clarified mouse spinal cord.  
(From Chung et al., Nature, 2013) 
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3. Results 
 
3.1 Characterization of STOML3 in vivo expression pattern 
 
STOML3 was first identified as an olfactory epithelium specific protein, whose role 
was consistent with the assembly, translocation, or function of the odorant 
transduction complex in olfactory neurons (Kobayakawa et al., 2002). Because of the 
selective localization of the Stoml3 mRNA to the olfactory cells, early studies 
suggested a specific role for the protein in the unique transduction pathway of 
olfactory neurons (Goldstein et al., 2003). STOML3 has an homologue in C. Elegans, 
MEC-2, which acts as a linker between MEC-4/MEC-10 ion channel and the 
cytoskeleton; its essential role in mechanotransduction was then demonstrated 
(Wetzel et al., 2007) 
To characterize the in-vivo expression pattern of STOML3, I investigated olfactory 
bulb, the whole spinal cord and lumbar DRGs of a reporter Stoml3LacZ mouse line, in 
which a β-galactosidase cassette with a nuclear localization signal (NLS) was inserted 
in place of the first exon of the Stoml3 gene under the control of Stoml3 promoter. 
This assay allows detecting β-galactosidase activity, which reflects the endogenous 
activity of the Stoml3 promoter, and thus sensory neurons that normally express 
STOML3 by means of a blu-violet spot located next to the nucleus that can be seen 
under a bright-field microscope. However, due to the nuclear localization of the signal 
sequence, X-gal staining does not predict the subcellular localization of the gene.  
In general, X-gal staining in Stoml3lacZ adult mice gave a robust signal only in olfactory 
bulb, whereas it gave a quite modest staining in spinal cord and lumbar DRGs due to a 
low expression of the gene.   
  
 
44 
 
Olfactory bulb. It has a laminar architecture with interneuron cell bodies lying 
around and beneath the outer stratum, called the glomerular layer, that receives 
direct input from olfactory nerves. An external plexiform layer, containing astrocytes 
and interneurons, links the glomerular layer with the more internal mitral layer which 
projects to olfactory cortex. In the center of the olfactory bulb, lies the granule cell 
layer.  
X-gal assay revealed a robust STOML3 expression in the glomerular layer, in which 
separate glomeruli developed a pronounced staining, and a moderate expression in 
the mitral layer (Fig. 5 a, b). 
 
Spinal cord. Transverse sections of spinal cord from Stoml3lacZ mice showed a 
strong signal in cells lining the central canal, with rare additional cells modest 
staining all over the gray matter, revealing a restricted pattern with a prominent 
staining in certain cells in ependyma (Fig. 5 c, d). 
Lumbar DRGs. The evidence that STOML3 null mice show a loss of 
mechanosensitivity in about 35% of skin mechanoreceptors (Wetzel et al., 2007) lead  
to investigate whether it can be due to a restricted expression of STOML3 by a 
distinct neuronal subpopulation; L4-L6 lumbar DRG sections were thus analyzed. 
Interestingly, only about 35-40% of DRG neurons developed an enzymatic reaction 
and expressed β-gal activity; in addition, only large- and medium-sized neurons 
developed a visible staining, as morphometrical analysis confirmed (Fig. 6 a, b, c). It 
can be thus assumed that STOML3 expression is restricted to a sub-population of 
mechanoreceptor sensory neurons. 
Stoml3 gene expression with ageing. The observation that Stoml3-/- mice are 
largely protected from mechanical neuropathic symptoms led to hypothesize that 
STOML3 could be considered an important factor in the onset of sensory disorders. A 
decline in the main sensory modalities, including touch sensation is widely reported 
to occur with ageing. A decrease of Stoml3 gene expression would be then related to 
loss of mechanosensitivity, as well as in raising the sensitivity to brush field under 
certain neuropathic conditions. Therefore, I asked whether STOML3 would have a 
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role in decreasing touch sensation with advancing age. Quantitative real-time PCR 
(qPCR) of lumbar L4-6 DRGs from wild type mice revealed a significant down-
regulation of Stoml3 mRNA copy number in 12 weeks old compared to 42 weeks old 
mice (Fig. 6 d), suggesting a role for STOML3 in the decline of mechanosensitivity 
with advancing age. Further electrophysiological experiments should be carried out 
in old mice in order to investigate changes in mechanical sensitivity.   
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Figure 6. (a) Transverse section of Olfactory Bulb. (b) Magnified region (20X) of the 
glomerular layer, separate glomeruli develop X-gal coloration. 
(c) Transverse sections of the lumbar region of Spinal Cord; STOML3 endogenous expression 
is restricted to cells surrounding the central canal (d) Magnified region (40X) of the central 
canal. Bar – 20 µm 
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Figure 7. (a) Stoml3 endogenous expression in lumbar DRGs. Bar – 20micron. (b) X-gal 
positive staining is restricted to medium and large sized-neurons. Quantitative real-time PCR 
(qPCR) revealed a significant down-regulation of Stoml3 mRNA copy number in 12 weeks old 
mice compared to 42 weeks old mice (***p<0.001; Student T- test; error bars indicate s.e.m.). 
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3.2 Characterization of CCI mice 
 
3.2.1 Mechanical and Behavioral assessment 
STOML3 is a membrane-associate protein expressed in sensory neurons and 
selectively associated to skin mechanoreceptors required for normal touch sensation 
in mouse. Electrophysiological recordings in STOML3 null mice indicate that a large 
proportion (about 45%) of rapidly adapting mechanoreceptors (RAM) fibers were 
unresponsive to very fast movements; the stimulus response in slowly adapting 
mechanoreceptors (SAM) was mildly but significantly impaired; the remaining RAM 
fibers and the D-hair fibers had normal mechanosensitivity. In addition, Aδ-fiber 
mechano-nociceptors and C-fibre nociceptors both displayed normal 
mechanosensitivity in Stoml3 mutant mice (Wetzel et al., 2007).   
Under neuropathic conditions, stimulation of low-threshold mechanoreceptors by 
brushing the skin can lead to intense pain in humans and animals.  In order to 
establish the presence of mechanical allodynia, C57BL/6N wild type and Stoml3-/- 
mice were both subjected to a unilateral sciatic nerve chronic constriction injury 
(CCI).  
The complete absence of Stoml3 mRNA expression in Stoml3-/- animals was 
confirmed by qPCR. Mechanical allodynia was assessed with Von Frey hairs using the 
Von Frey adapted up-down method, while thermal hyperalgesia symptoms were 
evaluated by measuring paw withdrawal latency in seconds by using Hargreaves 
method. Baseline withdrawal thresholds did not differ in wild type and Stoml3-/- mice 
before the surgery. After being subjected to CCI, wild type mice developed within a 
few days a full-blown allodynia with mechanical thresholds for paw withdrawal 
decreasing from 1.2 g to 0.04 g until the end of the measurements; thermal 
hyperalgesia symptoms were also fully developed with the withdrawal latency 
dropping down from 5 seconds to 3 seconds (Fig. 7 a, b). In contrast, STOML3 null 
mice did not show any mechanical hyperalgesia until the third day of lesion, and 
mechanical threshold decreased to just 0.6 g until the end of the observation period. 
Thermal withdrawal thresholds did no differ between control and STOML3 null mice 
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(Fig. 7 a, b); after 15 days both seemed to recover, as the paw withdrawal latency 
started to go up again (data not shown).  
 
 
3.2.2  Spinal glia response in CCI mice 
There is a rapidly growing body of evidence indicating that spinal microglia signalling plays a 
key role in the pathogenesis of neuropathic pain; glia inhibitors or glia modifying compounds 
can alter pain sensitivity, making glial cells an interesting target for neuropathic pain 
treatment.  
Clear, Lipid-exchanged, Acrylamide-hybridized Rigid, Imaging/immunostaining compatible, Tissue 
hYdrogel, (CLARITY), is a novel imaging technique (Chung et al., 2013) that allows to 
transform intact biological structures into a hybrid form in which tissue components are 
removed and replaced with exogenous elements for increased accessibility and functionality. 
This technique makes tissues see-through without destroy the tissue structure. When 
accompanied with antibody labeling, Clarity provides detailed pictures of fine structure, 
proteins and nucleic acids. I applied this method in transgenic McGreen mice, generously 
provided by Prof. Helmut Kettenman, in which the Cx3cr1 gene has been replaced by the 
enhanced Green Fluorescent Protein (eGFP) reporter gene, so that microglia can be directly 
visualized as fluorescent elements without using antibodies.  
Adult McGreen mice were subjected to CCI as described before. After assessing 
development of the neuropathic symptoms, spinal cord of naïve and CCI McGreen 
mice were dissected out and processed for CLARITY technique; microglia is here 
identified by means of CX3CR1 expression in CX3CR1-GFP mice.  
Z-stack confocal images from the dorsal to the ventral side of the lumbar spinal cord 
showed detailed pictures of microglia distribution. 3-D stacks from naïve mice 
displayed that microglia distribution do not differ between spinal cord antimeres 
(Fig. 8 a, b, c);  in CCI mice microglia appears to migrate and accumulate at focal sites 
of injury in the area where damaged axons project to. Nerve injury inducted-
microglial reaction is remarkable in the ipsilateral side of spinal cord (right side of the 
picture) which illustrates the enlarged and amoeboid morphological features of 
activated microglia cell bodies (Fig. 9 a, b).  
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In addition, the number of microglial cells and astrocytes increases in spinal dorsal 
horn ipsilaterally to a peripheral nerve injury (Fig. 9 a, b) while, approaching the 
ventral horn, both sides show the typical resting microglia morphology with no 
longer differences between ipsi- and contralateral side (Fig. 9, c, d, e).  
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a.                                                          b.  
 
 
 
Figure 8. (a) Baseline withdrawal thresholds did not differ in wild type and Stoml3-/- mice 
before the surgery (naïve mice). After being subjected to CCI, wild type mice developed 
within a few days a full-blown allodynia with mechanical thresholds for paw withdrawal 
decreasing from 1.2 g to 0.04 g until the end of the measurements. In contrast, STOML3 null 
mice did not show any mechanical hyperalgesia until the third day of lesion, and mechanical 
threshold decreased to 0.6 g until the end of the observation period. (b) Thermal 
hyperalgesia symptoms were developed with the withdrawal latency dropping down from 5 
seconds to 3 seconds. Thermal withdrawal thresholds did no differ between control and 
STOML3 null mice. 
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Figure 9. Confocal images of lumbar Spinal Cord from naïve McGreen mice show an equal 
microglia distribution between spinal cord antimeres from dorsal to ventral horn (a, b, c). 
Magnification: 10X. 
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Figure 10. (a,b) Nerve injury induces marked microglial reaction in the ipsilateral lumbar 
spinal cord. The contralateral side (left) shows the typical resting microglial morphology; the 
ipsilateral side (right) illustrates the enlarged and amoeboid morphological features of 
activated microglia cell bodies. Approaching the ventral horn, microglia shows the typical 
resting morphology and no longer differs between the ipsi- and contralateral sides (c, d, e). 
Magnification: 5X. 
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3.4 Stoml3 gene expression in CCI mice     
 
Wild type mice were subjected to unilateral CCI; after assessing the development of 
mechanical allodynia symptoms by using Von Frey hairs as described before, L4-L5 
DRGs were dissected out and processed in order to investigate Stoml3 mRNA copy 
number in injured and uninjured side. In parallel, lumbar DRGs from naïve mice were 
also processed in order to obtain endogenous Stoml3 mRNA copy number. 
Consistently with the histological data, qPCR revealed a quite low basal expression of 
Stoml3 transcript; copy number did not differ between left and right lumbar DRGs of 
naive mice.  However, Stoml3 mRNA levels in L4-L6 DRGs that project axons to the 
ligation site was doubled compared to the control (mRNA copy no. 75.57±1.54 
compared to 34.9±0.72, p<0.05; Mann-Whitney U test). By contrast, contralateral to 
the injury side no changes in Stoml3 transcript levels were observed (Fig. 10 f). 
Analysis from Stoml3lacZ mice revealed that STOML3 endogenous expression is 
restricted to large- and medium-sized cells; in addition, qPCR revealed a remarkable 
up-regulation of Stoml3 transcript in lumbar DRGs that project to the injured side.  By 
means of X-gal staining, as described before, I next investigated STOML3 expression 
pattern under neuropathic conditions in Stoml3lacZ/+ heterozygous mice, in which only 
one allele is replaced by the β-galactosidase cassette.  
Since genomic manipulation can alter the mice phenotype, in order to verify whether 
Stoml3lacZ/+ heterozygous mice displayed a normal mechanical sensitivity, mice were 
subjected to CCI in order to induce neuropathic pain; Von Frey up-down method was 
used to assess the development of neuropathic symptoms as described before.  Mice 
displayed no differences in mechanical sensitivity in both paws before the lesion, 
while the development of mechanical hyperalgesia identical to that occurring in wild 
type mice was measured in the post-injury early stage until the end of the assessment 
(data not shown). 
Lumbar DRGs from ipsi- and contralateral side to the injury were then dissected out 
and processed for X-gal staining. In heterozygous mice the staining appeared weaker 
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than that detected in Stoml3lacZ. However, morphometric analysis of  histological 
slices obtained from lumbar DRGs located in the lesion side displayed a number of 
lacZ-positive neurons more than doubled and with a more robust staining compared 
to the contralateral ones (105 stained cells in ipsilateral compared to 55 in 
contralateral DRGs; p<0.001, Chi-squared test). Again, cells fell predominantly in the 
large- to medium-size range, corroborating qPCR data on Stoml3 mRNA and the 
above reported results on the STOML3 endogenous expression pattern. 
Surprisingly, only DRG slices from the unilateral lesion side revealed a positive 
staining localized to cellular elements in the epineurium, possibly of immune nature, 
suggesting that under neuropathic conditions STOML3 might go through a 
phenotypic plasticity which increases the pain hypersensitivity.  
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Figure 11.  Immunostaining from Stoml3+/LacZ mice that had received the chronic constriction 
injury (CCI) shows an increase of stained cells in the ipsilateral DRGs (a) compared to the 
contralateral (b). LacZ-positive neurons fell predominantly in large cells in the ipsi-(c) and 
contralateral (d) DRGs. The number of LacZ positive neurons is significantly increased after 
CCI (***p<0.001; Chi-squared test; data are displayed as percentage neurons).  (f) Stoml3 
copy number derived from L4-6 (two mice per preparation) determined using real-time PCR 
shows an ipsilateral up-regulation of Stoml3 mRNA; the two last bars represent data from 
Stoml3-/- mice (**p<0.01, *p<0.05; Mann-Whitney U test; error bars indicate s.e.m.). 
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Figure 12. Lumbar DRGs show a de novo staining after CCI. X-gal staining of lumbar DRGs 
from Stoml3+/LacZ mice that received the nerve injury revealed positive cells in the epineurium 
of  ganglia  ipsilateral to the injury (a, b) which is not detectable in  contralateral ganglia from 
the same mice (c, d). Bar-40 µm.  
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3.5 Effect of peripheral STOML3 blockade on tactile 
allodynia in neuropathic mice  
 
Many cutaneous mechanoreceptors in Stoml3-/- mice innervate the skin but cannot be 
activated by mechanical stimulation (Moshourab et al., 2013; Wetzel et al., 2007); in 
addition,  STOML3 null mice are largely protected from tactile allodynia symptoms, 
but not from the thermal hyperalgesia. These observations led to hypothesize that 
modulation of mechanotransduction could somehow control the severity of 
neuropathic pain symptoms through STOML3 modulation.  
It has been recently demonstrated that the modulation of mechanotransduction by 
STOML3 depends on his capability to oligomerize (Brand et al., 2012); in order to 
identify a compound that would be able to disrupt or even enhance STOML3 function, 
a huge screening of molecules by using Bimolecular Fluorescence Complementation 
assay (BiFC) was made. With this assay the site of protein–protein interaction can be 
monitored as a fluorescence signal in cells when two fragments of a fluorescent 
protein fused to interacting proteins come together (Hu and  Kerppola, 2003).   
In particular, N- and C- terminal halves of YFP molecule are tagged to the intracellular 
termini of STOML3, that thus functions as prey and bait protein; when the two halves 
of YFP, located at the STOML3 C-terminus, come within 5 nm from each other, a 
fluorescent signal that increases linearly over time is producted. Mutations in one 
STOML3 pair that disrupt dimerization or higher order interactions that take place 
via stomatin-domain specifically reduce the rate of signal development.  
After a preliminary screen of about 35000 small molecules obtained from the central 
compound collection at the FMP screening unit (www.chembionet.info), two 
inhibitors of STOML3 self-association, called Oligomerization Blocker 1 and 2 (OB-1 
and OB-2) and two enhancers of STOML3 self-association called Oligomerization 
Enhancer  1 and 2 (OE 1 and OE-2) were found.  By blocking STOML3 oligomerization 
it is possible to silence tactile afferents completely and specifically, so that many but 
not all nociceptive sensory neurons have unchanged sensitivity (data not shown). 
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OB-1 reverses tactile allodynia in CCI mice. Local subcutaneous injections 
of the OB-1 compound (250-500 pMol per paw) into the hairy skin of the mouse 
lateral foot innervated by saphenous nerve were done; application of OB-1 did not 
change withdrawal thresholds in naïve mice, as well as no difference was found 
between uninjured control and stoml3-/- mice; in addiction, no change in withdrawal 
latency for radiant heat stimuli was measured and OB-1 application to Stoml3-/- mice 
subjected to unilateral CCI did not reveal any difference between the ipsi- and 
contralateral paw (Fig. 12 a, b, c).  
Mice were thus subjected to unilateral CCI, and mechanical symptoms development 
was assessed by Von Frey adapted up-and-down method as described before. 
Following neurophatic symptoms fully development, a blinded interplantar injection 
of OB-1 to the paws of wild type mice with established neuropathic pain was done; it 
was then possible to observe a complete reversal of the tactile allodynia (0.075±0.02 
g CCI mice vs 1.13±0.5 OB1 treated, Fig. 12 d).  
The effect is maximal after 3 hours of injection consistent with the idea that OB-1 
prevents oligomerization of STOML3; the effects of OB-1 on tactile allodynia wore off 
slowly over the next 12 hours so that the effect was absent after 24 h (data not 
shown); The reversal of tactile allodynia was indistinguishable from that found with 
systemic gabapentin treatment (Fig. 12 e), a standard centrally acting drug in clinical 
use for the treatment of neuropathic pain (Dworkin et al., 2010). Application of a 
series of OB-1 concentration on the neuropathic paw allowed determining a half-
maximal effective dose (ED50) of 4.42 µM (or approximately 20 pmol per paw) (Fig. 
12, f).  
 
 
OB-1 does not affect Stoml3 gene expression. OB-1 is able to prevent 
STOML3 dimerization and higher order of oligomerization, affecting the native 
mechanosensitivity currents similar to the results obtained from Stoml3-/- mice; 
intraplantar local injection of OB-1 has been shown to revert mechanical hyperalgesia 
symptoms in CCI mice, in which Stoml3 mRNA is significantly up-regulated. Thus, I 
next asked whether the effect of OB-1 and OE-1 could lead to changes on Stoml3 
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mRNA transcript. We thus exposed acutely isolated sensory neurons to 20 µM of each 
OB-1 and OE-1 for 3 hours in order to measure stoml3 mRNA copy number. qPCR 
revealed that OB-1 and OE-1 treatment do not lead to any change in the level of 
stoml3 mRNA transcript (Fig. 12 g).  Cultured N2A cells were treated as well for 3 
hours with 20 µM of OB-1 and OE-1. Again, qPCR did not display any change in mRNA 
copy number, suggesting that these molecules exert their effect without regulating 
Stoml3 gene expression.  
Inflammatory pain is not dependent on STOML3. Systemic dosing with 
Nerve Growth Factor provokes inflammatory pain. In this model mechanical and 
thermal hyperalgesia are prominent features, and they are largely dependent on an 
increased NGF level (Lewin et al., 2014).  Systemic injection of NGF (1 mg/kg) in 
naïve and Stoml3-/- mice provokes long lasting mechanical and thermal hyperalgesia 
in both mice strains without any remarkable difference; in addition, these symptoms 
are not reversed by local application of OB-1 (Fig. 13 a), suggesting that heat 
hyperalgesia is not dependent on STOML3and thus is not influenced by OB-1 effect. 
 
STOML3 is the major target in OB-1 mediate symptom relief. 
Neuropathic pain can be induced by means of several models. CCI model cause a 
direct damage to the axons that innervate the skin of the plantar hindpaw (Basbaum 
et al., 1991). However, other models that cause hyperalgesia to the skin in the same 
part of the leg do not involve direct injury to the sensory afferents. Spare nerve injury 
(SNI) induces hypersensitivity of the plantar hind-paw by cutting nerves adjacent to 
the tibial nerve that supplies both efferent and afferent innervation to the plantar foot 
(Decosterd et al., 2000; Shields et al., 2003).   
Wild type mice were subjected to SNI, and then Von Frey up and down test was used 
to monitorate the development of allodynia as described before. Mice showed a long 
lasting mechanical hypersensitivity of a similar magnitude to that observed in CCI 
with the average of withdrawal threshold ranging from 1 g before the surgery to 
0.004 g few days after the surgery until the end of the measurements (Fig. 14, a).  
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A local dose of OB-1 was then injected as described before; surprisingly, application 
of OB-1 to the plantar skin did not produce reversal of mechanical hypersensitivity 
(Fig. 14, b) 
We next dissected out lumbar DRGs from SNI mice in order to investigate Stoml3 
mRNA level by quantitative real-time PCR. Interestingly,  no changes of mRNA 
transcripts levels between the injured and uninjured side was found in this model 
(Fig. 14, c), suggesting  that the up-regulation of STOML3 in CCI model is 
pathophysiologically relevant for the development of touch hypersensitivity in this 
model , and thus that STOML3  as the major target in OB-1 mediate symptom relief. 
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Figure 13. Self-association of stomatin-domain proteins can be monitored using BiFC 
whereby N-and C-terminal halves of YFP molecule are tagged to the prey and bait protein 
STOML3. Wild type STOML3 was used as both the bait and the prey. 
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Figure 14. (a) Paw withdrawal thresholds (PWT) show that naïve mice do not respond to 
local OB-1 interplantar treatment. (b) Paw withdrawal latencies (PWT) to a radiant heat 
beam applied to the hind paw show that naïve wild type mice do not respond to OB-1 
treatment. (c) PWTs of STOML3 null mice do not change after localOB-1 treatment. (d) PWTs 
show that Stoml3-/- mice develop significantly less touch-evoked pain symptoms compared to 
wild type animals (***p<0.001, two-way ANOVA).  (e) After interplantar application of OB-1 
to the paw of mice with established neuropathic pain, a complete reversal of tactile-evoked 
pain can be observed (OB-1 treated p<0.001; Mann Whitney U-test); OB-1 relieve of touch-
evoked pain is indistinguishable from gabapentin treated mice (f) OB-1 has an half-maximal 
effective dose (ED50) of 4.42 µM (approximately 20 pmol per paw). (g) N2A cells and acutely 
isolated DRGs were treated with either vehicle, OB-1 orOE-1 (20 µM) for 3 hour before mRNA 
isolation, reverse transcription and qRT-PCR; no difference in Stoml3 transcript was 
detected. 
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Figure 15. (a, b) PWTs and PWLs before and after NGF-induced hyperalgesia indicate no 
changes between genotypes. (c, d) OB-1 do not alleviate NGF-induced mechanical and 
thermal hyperalgesia. Numbers indicate mice treated; data are displayed as mean PWL/PWL 
± s.e.m. 
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Figure 16. (a) Development of tactile-evoked pain using the spare nerve injury (SNI) model. 
Wild type mice develop a prolonged tactile-evoked pain ipsilateral to the injury (***p<0.001; 
Two way ANOVA; error bars indicate s.e.m.).  (b) PTWs are measured showing no alleviation 
of tactile-evoked pain after local OB-1 treatment. (c) Stoml3 copy number from lumbar DRGs 
determined using real-time PCR showed no up-regulation of Stoml3 mRNA after SNI.  
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4. Discussion 
 
 
The DRG primary sensory neurons transduce mechanical signals at their nerve 
endings via mechanically-gated ion channels, the activation of which depolarizes 
nerve endings to initiate spikes (Drew, Wood, & Cesare, 2002; Hu & Lewin, 2006; 
Lechner & Lewin, 2013; McCarter, Reichling, & Levine, 1999), detecting the sense of 
touch and pain.  
Mammals touch sensation still remains poorly understood at the molecular level, 
even though recent findings of novel families of proteins acting as mechanosensing 
molecules has undoubtedly accelerated our understanding of mechanotransduction 
mechanisms in mammalian somatosensation. Recent data indicate that Piezo2 is the 
critical transducer of mechanical stimuli in sensory neurons, and its sensitivity can be 
modulated by STOML3 by nanometer-scale stimuli (Poole et al., 2014; Ranade et al., 
2014; Schrenk-Siemens et al., 2015; Wetzel et al., 2007).  
STOML3 has been demonstrated to be necessary for the function of at least 35% of 
the mechanoreceptors; in addition STOML3 null mice are also largely protected from 
touch-evoked pain under neuropathic conditions (Wetzel et al., 2007). 
Neuropathic pain is a debilitating condition  whose key feature is represented by the 
so-called touch-evoked pain, initiated upon activation of low threshold 
mechanoreceptors (Costigan et al., 2009; Lewin & Moshourab, 2004; von Hehn et al., 
2012; Tal & Bennet, 1994). The remarkable protection from touch-evocked pain in 
STOML3 null mice lead to hypothesize a role for STOML3 in neuropathic pain; in that 
case, enhancing or inhibiting touch sensitivity with small molecules would be 
desirable for treating a variety of sensory disorders. Inhibition of touch receptor 
function could be then used to treat the extreme pain experienced by neuropathic 
pain patients when subjected to the slightest brush of a feather (Costigan et al., 2009; 
von Hehn et al., 2012).  
The data presented on this thesis revealed that STOML3 is a key contributor in a 
murine model of neuropathic pain and a promising target in neuropathic pain 
67 
 
treatment through the modulation of mechanoreceptor function at the level of 
transduction with small molecule inhibitors of STOML3 oligomerization.   
 
STOML3 in-vivo expression pattern.  
Spinal cord. Consistent with previous qPCR data, immunohistochemical analysis 
carried out in the spinal cord showed a staining restricted to cells surrounding the 
central canal and few other cells in the gray matter. The central canal is a 
cerebrospinal fluid (CSF) -filled cavity that runs through the spinal cord is continuous 
anteriorly with the ventricular system of the brain and enlarges at the region of the 
obex to become the 4th ventricle. It represents the remainder of the neural canal in 
adults, and is lined with ependyma, a thin epithelium-like membrane composed by 
ependymal cells, a neuroglia cell-type with several recognized roles among which the 
CSF production and circulation through the ventricular cavities. It has been reported 
that in the spinal cord, central canal ependymal cells possess latent neural stem cell 
properties and that injury induces proliferation of ependymal cells and migration of 
ependyma-derived progeny towards the site of injury (Meletis et al., 2008; Hamilton 
et al., 2009; Mothe & Tator, 2005; Marichal et al., 2009). Considering that STOML3 
shows a preferential neuronal expression, future phenotypical characterization of the 
STOML3-βgal  positive ependymal-like cells with such markers like doublecortin 
(DCX) and poly-sialylated neuronal cell adhesion molecule (PSA-NCAM), typical of 
migrating neuroblasts, should be done in order to verify their nature. 
Lumbar DRGs.  qPCR data revealed a quite low expression of mRNA copy number 
in L4-L6 DRGs; further histological analysis allowed me to show that Stoml3 
expression is restricted to large- and medium-sized neurons, which fell in the range of 
Aβ- and Aδ-fibers, respectively.  
Almost all large diameter sensory neurons isolated from wild type mice possess a fast 
and sensitive mechanically gated current (Hu, Chiang, Koch, & Lewin, 2010; Hu & 
Lewin, 2006; Lechner et al., 2009). Mechanosensitive currents require the presence of 
STOML-3, as they were absent in large diameter neurons isolated from Stoml3−/− mice 
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and could be rescued after reintroduction of a cDNA encoding wild type STOML-3 
(Wetzel et al., 2007). Thus, it can be assumed that the reported lack of 
mechanosensitivity is due to a restricted expression of STOML3 to a distinct 
subpopulation of mechanosensitive sensory neurons.  
 
Stoml3 decreases with ageing. An age-related decline in the main sensory 
modalities is well reported; therefore, a loss of mechanosensitivity with advancing 
age would be expected. However, studying and interpreting the effect of ageing on 
touch is still matter of studies. Some studies have pointed out a change in peripheral 
components of touch perception with advancing age, highlighting that ageing 
influences several morphological and functional features of the peripheral nervous 
system. I thus asked whether a decrease of Stoml3 gene expression could be related 
to a loss of mechanosensitivity. Quantitative real-time PCR revealed a significant 
down-regulation of Stoml3 mRNA copy number in 12 weeks old mice compared to 42 
weeks old mice, suggesting that a loss of the normal mechanosensitivity with ageing 
could be also related to decreasing of Stoml3 mRNA expression in sensory neurons. 
Electrophysiological properties of mechanosensitive currents in old mice are by now 
under investigation.  
 
 
Stoml3 gene expression in CCI mice 
STOML3 null mice are largely protected from touch-evoked pain after being subjected 
to a unilateral chronic constriction injury (Wetzel et al., 2007). Baseline paw 
withdrawal thresholds in wild type and Stoml3-/- mice did not differ, as measured 
with von Frey adapted up-down method. However, after induction of a unilateral CCI, 
paw withdrawal thresholds dropped profoundly in wild type mice but were only 
moderately reduced in Stoml3-/- mice.  
The remarkable protection from touch-evoked pain in animals lacking STOML3 led to 
hypothesize that the nerve injury may itself lead to a change in the levels of Stoml3 
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mRNA expression in the DRG. Quantitative PCR measured a doubling in Stoml3 mRNA 
expression levels in the lumbar DRGs that project axons to the ligation site compared 
to control, while no change was found on the side contralateral to the injury. In 
addition, by using Stoml3+/lacZ knock in mice, I have also revealed a doubling in the 
number of lacZ positive neurons in the L6-L4 ipsilateral ganglia after a unilateral CCI, 
with stained cells that fell predominantly in the large to medium sized-range.  
These data are consistent with the idea that chronic nerve constriction leads to an 
increase in the number of large and medium sized sensory neurons and that up-
regulation of STOML3 could in turn exacerbate touch-evoked pain by enhancing the  
sensitivity of mechanotransduction in sensory afferents within the injured nerve.  
Surprisingly, DRG epineurium displayed positive staining localized to cellular 
elements only restricted to lumbar DRGs that project to the CCI side.  
Incomplete nerve damage by a CCI of the sciatic nerve induces pain behavior and is 
accompanied by a profound local inflammatory response which includes the 
infiltration of immune cells (Stoll and Muller, 1999; Sommer et al., 2001). Adult 
neuropathic pain is characterized by microglia activation, T-cells infiltration and the 
release of pro-inflammatory immune mediators in the dorsal horn, critical for 
sensibilization and pain-like hypersensitivity (Taves et al., 2013; Tsuda et al., 2013).  
Macrophages, neutrophils, CD4+ T-cells and immune-like glial cells (such as 
microglia) are known to respond to nerve injury by alterating intercellular signalling 
and by migrating to areas of inflammation within the peripheral and central nervous 
system (Ren et al., 2010). 
 It has been recently demonstrated that degenerated peripheral nerves are also 
infiltrated by T-cells (Moalem et al., 1999; Moalem et al., 2004); cytokine-mediate 
signalling and CD4+ T-cells have been shown to have a relevant contribution in the 
development of neuropathic pain (Sommer et al., 2004; Molaem et al., 2004). T-cells 
are the principal source of IL-17, have immune modulating properties and 
coordinates local tissue inflammation via the release of other pro-inflammatory 
cytokines and chemokines (Kolls & Linden 2004). Moreover, congenitally athymic 
nude rats, which lack mature T-cells, developed reduced mechanical allodynia and 
thermal hyperalgesia (Molaem et al., 2004). 
70 
 
It might be possible that de novo expression of STOML3 in T- cells, which may occur in 
neuropathic conditions, can also contribute at the mechano-hypersensitivity; 
additional analysis of co-localization with specific markers of immunological cells 
such as IL 17 has to be done in order to investigate the nature of cells that seem to 
acquire de novo the ability to express STOML3 only under neuropathic conditions. 
 
 
Effect of STOML3 peripheral blockade in neuropathic pain  
The modulation of mechanotransduction by STOML3 is dependent on its ability to 
oligomerize (Brand et al., 2012; Poole et al., 2014). This key fact prompted to design a 
small molecule strategy to modulate STOML3 activity and thereby mechanoreceptor 
sensitivity. Molecules that decrease STOML3 self-association block the ability of 
STOML3 to modulate Piezo channels and small molecules that enhance STOML3 self-
association can sensitize Piezo channels to molecular scale movements. The discovery 
of mechanotransduction modulating drugs opens the possibility that optimized lead 
molecules that are active peripherally can be rapidly developed to treat this 
condition. 
By blocking STOML3 oligomerization it can be possible to silence tactile afferents 
completely and specifically, so that many but not all nociceptive sensory neurons 
have unchanged sensitivity (data not shown). The results presented in this thesis 
revealed that OB-1 treatment on CCI mice reverses well-established touch-evoked 
neuropathic symptoms. In addition, quantitative Stoml3 mRNA analysis revealed no 
changes of Stoml3 gene expression in lumbar DRGs and N2A cells after OB-1 
treatment for 3 hours, consistent with the hypothesis that the compound do not affect 
gene expression but it only silences tactile afferents blocking STOML3 
oligomerization at the protein level. The effect of OB-1 is local and reversible after 24 
hours from the treatment, leading to control touch sensitivity in vivo with both 
temporal and spatial precision without affecting the axon excitability in vivo (data not 
shown). In addition, the observation that OB-1 has no effect in changing Stoml3-/- paw 
withdrawal thresholds led to assume that the compound effects do not  take place via 
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other Stomatin domains, but that STOML3 is the main effector of OB-1 mediated 
symptom relief. 
Chronic constriction injury (CCI) represent a model of well established neuropathic 
symptoms which can be well related to the human condition; however, it does not 
enable injured and not-injured axons to be identified. Furthermore, it has been 
demonstrated a near complete loss of large myelinated fibers distal to the ligature in 
rat (Basbaum, 1991). 
By using one variant of the spared nerve injury model (SNI) in mice, new experiments 
were carried out, whose results were surprising but provide new insight into the role 
of STOML3 in driving neuropathic pain. Von Frey thresholds on the side ipsilateral to 
the injury dropped to levels comparable to those observed in CCI model; however, 
OB-1 compound did not reverse the mechanical hypersensitivity.  
The main difference between these two models of induced peripheral neuropathies is 
that many of the axons that innervate the sensitized area of the foot in the CCI model 
are indeed directly damaged; in contrast, the afferents innervating the sensitized area 
in SNI model are not damaged. In addition, minor changes in mechanoreceptors 
function have been shown to occur in the spinal nerve ligation model (Na et al., 1993).  
I revealed that Stoml3 mRNA is selectively up-regulated in DRG neurons subjected to 
a neuropathic nerve injury; however, I did not observe any changes in Stoml3 
expression in sensory neurons subjected to axotomy per se. 
These data suggest that physiological changes in injured afferents may be dependent 
on STOML3 regulation and significantly contribute to the severity of neuropathic pain 
symptoms; thus, the analgesic effect of OB-1 seems to be associated with a relevant 
up-regulation of STOML3 in CCI damaged sensory afferents.  
In conclusion, the data presented in this thesis show that STOML3 is an important 
contributor and a promising pharmacological target in a mouse model of chronic 
neuropathic pain, and that by targeting STOML3 oligomerization with small 
molecules it can be possible tuning mechanotransduction in either direction, to 
inhibit or enhance sensitivity, leading the possibility of treating the mechanical 
hyperalgesia symptoms of several forms of neurological disorders where touch 
sensation is disturbed.  
72 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
73 
 
 References 
Aldskogius, Ê. K. a N., & Kozlova, E. N. (1998). Central Neuron ± Glial and Glial ± Glial 
Interactions Following Axon Injury, 55(97). 
Baker, M. D., & Wood, J. N. (2001). Involvement of Na+ channels in pain pathways. 
Trends in Pharmacological Sciences, 22(1), 27–31.  
Basbaum A. I., Levine J. D. (1991) The contribution of the nervous system to 
inflammation and inflammatory disease. Can J Physiol Pharmacol. 69(5), 647-51. 
Beggs, S., Trang, T., Salter, W. M. (2012) P2X4R+ microglia drive neuropathic pain. 
Nature Neuroscience, 15, 1068–1073. 
Bennett, G. J., & Xie, Y. K. (1988). A peripheral mononeuropathy in rat that produces 
disorders of pain sensation like those seen in man. Pain, 33, 87–107.  
Brand, J., Smith, E. S. J., Schwefel, D., Lapatsina, L., Poole, K., Omerbašić, D., … Daumke, 
O. (2012). A stomatin dimer modulates the activity of acid-sensing ion channels. 
The EMBO Journal, 31(17), 3635–3646.  
Chalfie, M., & Sulston J. Developmental genetics of the mechanosensory neurons of 
Caenorhabditis Elegans (1981) Developmental  Biology., 82, 358-370. 
Chaplan, S. R., Bach, F. W., Pogrel, J. W., Chung, J. M., Yaksh, T. L. Quantitative 
assessment of tactile allodynia in the rat paw (1994) Journal of Neuroscience 
Methods, 53(1), 55-63.  
Chen Y., Devor M. (1998) Ectopic mechanosensitivity in injured sensory axons 
arises      from the site of spontaneous electrogenesis. European  Journal of  
Pain, 2, 165–178 
 
Chung K., Wallace, J., Kim, S., … Gradinaru, V., & Deisseroth K. (2013) Structural and 
molecular interrogation of intact biological systems. Nature, 497, 332-337 
Coste, B., Mathur, J., Schmidt, M., Earley, T. J., Ranade, S., Petrus, M. J., … Patapoutian, A. 
(2010). Piezo1 and Piezo2 are essential components of distinct mechanically-
activated cation channels Bertrand. Science, 330(6000), 55–60.  
Costigan, M., Scholz, J., & Woolf, C. J. (2009). Neuropathic pain: a maladaptive 
response of the nervous system to damage. Annual Review of Neuroscience 32, 1–
32.  
Stoll G., Jander S. (1999). The role of microglia and macrophages in the 
pathophysiology of the CNS. Prog Neurobiol 58, 233–247. 
74 
 
Decosterd I, Woolf CJ (2000). Spared nerve injury: an animal model of persistent 
peripheral neuropathic pain. Pain 87, 149-158. 
Devor, M., Jänig, W., & Michaelis, M. (1994). Modulation of activity in dorsal root 
ganglion neurons by sympathetic activation in nerve-injured rats. Journal of 
Neurophysiology, 71(1), 38–47. 
Drew, L. J., Wood, J. N., & Cesare, P. (2002). Distinct mechanosensitive properties of 
capsaicin-sensitive and -insensitive sensory neurons. The Journal of 
Neuroscience: The Official Journal of the Society for Neuroscience, 22(12), RC228. 
Goldstein B. J., Kulaga H. M., Reed R. R. (2003) Cloning and characterization of SPL3: a 
novel member of the stomatin family expressed in olfactory receptor neurons. 
Journal of the Association for research in Otolaryngology , 4(1), 74-82 
Goodman, M. B., Ernstrom, G. G., Chelur, D. S., O’Hagan, R., Yao, C. A., & Chalfie, M. 
(2002). MEC-2 regulates C. elegans DEG/ENaC channels needed for 
mechanosensation. Nature, 415(6875), 1039–1042.  
Green, J. B., & Young, J. P. W. (2008). Slipins: ancient origin, duplication and 
diversification of the stomatin protein family. BMC Evolutionary Biology, 8, 44.  
Gwak, Y. S., Crown, E. D., Unabia., G. C., Hulsebosch, C. E. (2008). Propentofylline 
attenuates allodynia, glial activation and modulates GABAergic tone after spinal 
cord injury in the rat. Pain, 138(2) 410-422 
Hamilton, L. K., Truong, M. K. V, Bednarczyk, M. R., Aumont, a., & Fernandes, K. J. L. 
(2009). Cellular organization of the central canal ependymal zone, a niche of 
latent neural stem cells in the adult mammalian spinal cord. Neuroscience, 
164(3), 1044–1056.  
Hu, J., Chiang, L.-Y., Koch, M., & Lewin, G. R. (2010). Evidence for a protein tether 
involved in somatic touch. The EMBO Journal, 29, 855–867.  
Hu, J., & Lewin, G. R. (2006). Mechanosensitive currents in the neurites of cultured 
mouse sensory neurones. The Journal of Physiology, 577, 815–828.  
Hu C. D., Kerppola T. K. (2003) Simultaneous visualization of multiple protein 
interactions in living cells using multicolor fluorescence complementation 
analysis. Nature Biotechnology., 21, 539-545. 
Kim, K. J., Yoon, Y. W., & Chung, J. M. (1997). Comparison of three rodent neuropathic 
pain models. Experimental Brain Research, 113, 200–206.  
Kobayakawa, K., Hayashi, R., Morita, K., Miyamichi, K., Oka, Y., Tsuboi, A., & Sakano, H. 
(2002). Stomatin-related olfactory protein, SRO, specifically expressed in the 
75 
 
murine olfactory sensory neurons. The Journal of Neuroscience  : The Official 
Journal of the Society for Neuroscience, 22(14), 5931–5937.  
Kolls, J. K. & Linden, A. (2004). Interleukin-17 family members and inflammation. 
Immunity, 21(4), 467-476.  
Lapatsina, L., Brand, J., Poole, K., Daumke, O., & Lewin, G. R. (2012). Stomatin-domain 
proteins. European Journal of Cell Biology, 91(4), 240–245.  
Lawson, S. N. (1992). Morphological and biochemical cell types of sensory neurons. 
Sensory Neurons: Diversity, development, and plasticity. New York (USA): Oxford 
University Press. p. 27-52 
Lechner, S. G., Frenzel, H., Wang, R., & Lewin, G. R. (2009). Developmental waves of 
mechanosensitivity acquisition in sensory neuron subtypes during embryonic 
development. The EMBO Journal, 28(10), 1479–1491.  
Lechner, S. G., & Lewin, G. R. (2013). Hairy sensation. Physiology (Bethesda, Md.), 
28(3), 142–150.  
Lewin, G. R., & Moshourab, R. (2004). Mechanosensation and pain. Journal of 
Neurobiology, 61(1), 30–44.  
Marichal N., García G., Radmilovich M., Trujillo-Cenóz O. & Russo R. E. (2009) 
Enigmatic central canal contacting cells: immature neurons in “standby mode”? 
Journal of  Neuroscience  29, 10010-10024 
McLachlan E. M., Jänig W., Devor M., Michaelis M. (1993) Peripheral nerve injury 
triggers noradrenergic sprouting within dorsal root ganglia. Nature 363, 543–
546. 
McCarter, G. C., Reichling, D. B., & Levine, J. D. (1999). Mechanical transduction by rat 
dorsal root ganglion neurons in vitro. Neuroscience Letters, 273(3), 179–182. 
McCarthy, P. W., & Lawson, S. N. (1990). Cell type and conduction velocity of rat 
primary sensory neurons with calcitonin gene-related peptide-like 
immunoreactivity. Neuroscience, 34(3), 623–632.  
Meletis K., Barnabé-Heider F., Carlén M., Evergren E., Tomilin N., Shupliakov O. & 
Frisén J. (2008) Spinal cord injury reveals multilineage differentiation of 
ependymal cells. PLoS Biology 6, e182 
Miki, K., Fukuoka, T., Tokunaga, a, & Noguchi, K. (1998). Calcitonin gene-related 
peptide increase in the rat spinal dorsal horn and dorsal column nucleus 
following peripheral nerve injury: up-regulation in a subpopulation of primary 
afferent sensory neurons. Neuroscience, 82(4), 1243–1252. 
76 
 
Milligan, E. D., Zapata, V., Chacur, M., Schoeniger, D., Biedenkapp, J., O&apos;Connor, K. 
a., … Watkins, L. R. (2004). Evidence that exogenous and endogenous fractalkine 
can induce spinal nociceptive facilitation in rats. European Journal of 
Neuroscience, 20, 2294–2302.  
Moalem, G., Leibowitz-Amit, R., Yoles, E., Mor, F., Cohen, I., R. & Schwartz, M. (1999)  
Autoimmune T-cells protect neurons from secondary degeneration after central 
nervous system axotomy. Nature Medicine, 5, 49-55. 
Moalem, G., Xu, K., Yu, L. (2004). T-lymphocyte play a role in neuropathic pain 
following peripheral nerve injury in rats. Neuroscience, 129, 767-777. 
Moshourab, R. a, Wetzel, C., Martinez-Salgado, C., & Lewin, G. R. (2013). Stomatin-
domain protein interactions with acid-sensing ion channels modulate nociceptor 
mechanosensitivity. The Journal of Physiology, 591(22), 5555–5574.  
Mothe, A., & Tator, C. (2005). Proliferation, migration, and differentiation of 
endogenous ependymal region stem/progenitor cells following minimal spinal 
cord injury in the adult rat. Neuroscience, 131, 177–187.  
Na, H. S., Leem, J. W., Chung, J. M. (1993) Abnormalities of mechanoreceptors in a rat 
model of neuropathic pain: possible involvement in mediating mechanical 
allodynia. Journal of Neurophysiology, 70, 522-528. 
O’Hagan, R., Chalfie, M., & Goodman, M. B. (2005). The MEC-4 DEG/ENaC channel of 
Caenorhabditis elegans touch receptor neurons transduces mechanical signals. 
Nature Neuroscience, 8(1), 43–50.  
Poole, K., Herget, R., Lapatsina, L., Ngo, H.-D., & Lewin, G. R. (2014). Tuning Piezo ion 
channels to detect molecular-scale movements relevant for fine touch. Nature 
Communications, 5, 3520.  
Price, M. P., McIlwrath, S. L., Xie, J., Cheng, C., Qiao, J., Tarr, D. E., … Welsh, M. J. (2001). 
The DRASIC cation channel contributes to the detection of cutaneous touch and 
acid stimuli in mice. Neuron, 32(6), 1071–1083.  
Ren, K., & Dubner, R. (2010) Interactions between the immune and nervous system in 
pain. Nature medicine, 16(11), 1267-1276. 
Ranade, S. S., Woo, S.-H., Dubin, A. E., Moshourab, R. A., Wetzel, C., Petrus, M., … 
Patapoutian, A. (2014). Piezo2 is the major transducer of mechanical forces for 
touch sensation in mice. Nature, 516(7529), 121–125.  
Roza, C., Puel, J.-L., Kress, M., Baron, A., Diochot, S., Lazdunski, M., & Waldmann, R. 
(2004). Knockout of the ASIC2 channel in mice does not impair cutaneous 
mechanosensation, visceral mechanonociception and hearing. The Journal of 
Physiology, 558(Pt 2), 659–669.  
77 
 
Schrenk-Siemens, K., Wende, H., Prato, V., Song, K., Rostock, C., Loewer, A., … Siemens, 
J. (2015). PIEZO2 is required for mechanotransduction in human stem cell-
derived touch receptors. Nature Neuroscience, 18(1), 10–16.  
Sommer, E. W., Kazimierczak, J., & Droz, B. (1985). Neuronal subpopulations in the 
dorsal root ganglion of the mouse as characterized by combination of 
ultrastructural and cytochemical features. Brain Research, 346, 310–326. 
Sommer C., Scha¨fers M., Marziniak M., Toyka K. V. (2001a) Etanercept reduces 
hyperalgesia in experimental painful neuropathy. J Peripher Nerv Syst 6:67–72.  
Sommer C., Lindenlaub T., Teuteberg P., Scha¨fers M., Hartung T., Toyka K. V. (2001b) 
Anti-TNF-neutralizing antibodies reduce pain-related behavior in two different 
mouse models of painful mononeuropathy. Brain Research 913, 86–89. 
Stoll, G., & Muller, H. W. (1999) Nerve injury, axonal degeneration and neural 
regeneration: Basic insights. Brain pathology, 9, 313-325. 
Tanga, F. Y., Raghavendra, V. & DeLeo, J. a. (2004). Quantitative real-time RT-PCR 
assessment of spinal microglial and astrocytic activation markers in a rat model 
of neuropathic pain. Neurochemistry International, 45, 397–407.  
Taves, S., Berta, T., Chen, G, Ji, R. R. (2013) Microglia and spinal cord synaptic 
plasticity in persistent pain. Neural Plasicity, 2013-753656. 
Tsuda M., Beggs S., Salter M. W., Inoue K. (2013) Microglia and intractable chronic 
pain. Glia, 61, 55–61. 
Tsuda M., Inoue K., Salter M. W. (2005). Neuropathic pain and spinal microglia: a big 
problem from molecules in “small” glia. Trends in Neuroscience, 28, 101–107 
Tsuda M., Shigemoto-Mogami Y., Koizumi S., Mizokoshi A., Kohsaka S., Salter M. W., et 
al. (2003). P2X4 receptors induced in spinal microglia gate tactile allodynia after 
nerve injury. Nature 424, 778–783 
von Hehn, C. A., Baron, R., & Woolf, C. J. (2012). Deconstructing the Neuropathic Pain 
Phenotype to Reveal Neural Mechanisms. Neuron, 73(4), 638–652.  
Wetzel, C., Hu, J., Riethmacher, D., Benckendorff, A., Harder, L., Eilers, A., … Lewin, G. R. 
(2007a). A stomatin-domain protein essential for touch sensation in the mouse. 
Nature, 445(7124), 206–209.  
Wetzel, C., Hu, J., Riethmacher, D., Benckendorff, A., Harder, L., Eilers, A., … Lewin, G. R. 
(2007b). A stomatin-domain protein essential for touch sensation in the mouse. 
Nature, 445, 206–209.  
78 
 
Woolf, C. J., & Mannion, R. J. (1999). Neuropathic pain: Aetiology, symptoms, 
mechanisms, and management. Lancet.  
Woolf, C. J., Safieh-Garabedian, B., Ma, Q. P., Crilly, P., & Winter, J. (1994). Nerve 
growth factor contributes to the generation of inflammatory sensory 
hypersensitivity. Neuroscience, 62(2), 327–331.  
Xie Y., Zhang J., Petersen M., LaMotte R. H. (1995) Functional changes in dorsal root 
ganglion cells after chronic nerve constriction in the rat. Journal of  
Neurophysiology 73(5), 1811–1820. 
 
